Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with or without cyclophosphamide and durvalumab for recurrent ovarian, fallopian tube, or primary peritoneal cancer
ACTRN12618000686202Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- May 2019
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, durvalumab and cyclophosphamide in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by The University of Sydney. Primary endpoint: 36-week progression-free survival rate. Started May 2019; status: completed.
02
Drugs
olaparibdurvalumabcyclophosphamide
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ACTRN12618000686202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000686202.